<DOC>
	<DOCNO>NCT00653848</DOCNO>
	<brief_summary>As docetaxel proven effective late stage prostate cancer large tumour burden effective primarily treat intermediate high risk prostate cancer adjuvant treatment radiotherapy prevent early relapse . This therefore test randomised phase III trial patient randomize either docetaxel surveillance</brief_summary>
	<brief_title>Treatment Prostate Cancer With Docetaxel + Hormonal Treatment Versus Hormonal Treatment Patients Treated With Radical Radiotherapy</brief_title>
	<detailed_description>Primary endpoint : - PSA progression rate , ASTRO guideline . Secondary endpoint : - PSA doubling time progression - Quality Life ( QoL ) - Safety - Metastases free survival - Overall survival</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Men &gt; 18 â‰¤75 year age . WHO/ECOG performance status 0 1 . Histological proven adenocarcinoma prostate within 12 month prior randomisation One following : T2 Gleason score 7 ( 4+3 ) PSA &gt; 10 ng/ml &lt; 70 ng/ml T2 Gleason 810 , PSA &lt; 70 ng/ml T3 tumour Prior neoadjuvant hormone therapy mandatory patient Adequate haematological , liver kidney function . ( Hemoglobin &gt; 110 g/l , neutrophils &gt; 1.5 x 109/ l , platelet &gt; 150 x 109/ l , ASAT ALAT &lt; 1.5 x ULN , ALP &lt; 1.5 x ULN , creatinine &lt; 1.5 x ULN ) Written informed consent M+ N+ clinical pathological Patients history previous malignant disease . Exceptions make basal cell carcinoma ( BCC ) squamous cell carcinoma skin . Exceptions also make curatively treated malignant disease , disease free past five year . Previous radiotherapy pelvic region . Previous chemotherapy within 5 year . Systemic corticosteroid within 6 month prior randomisation . Unstable cardiovascular disease , include myocardial infarction , within 6 month prior randomisation . Active untreated infectious disease , include tuberculosis , MRSA . Active gastric ulcer . Known hypersensitivity Polysorbate 80 ( excipient docetaxel ) Other serious illness medical condition</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Adjuvant treatment , intermediate high risk , radical radiotherapy</keyword>
</DOC>